WO1999006834A3 - Methods for identifying ligand specific binding molecules - Google Patents

Methods for identifying ligand specific binding molecules

Info

Publication number
WO1999006834A3
WO1999006834A3 PCT/US1998/016280 US9816280W WO9906834A3 WO 1999006834 A3 WO1999006834 A3 WO 1999006834A3 US 9816280 W US9816280 W US 9816280W WO 9906834 A3 WO9906834 A3 WO 9906834A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid support
diverse population
antibody
binding molecules
selective
Prior art date
Application number
PCT/US1998/016280
Other languages
French (fr)
Other versions
WO1999006834A2 (en
Inventor
Jeffry D Watkins
William D Huse
Herren Wu
Original Assignee
Ixsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ixsys Inc filed Critical Ixsys Inc
Priority to JP2000505515A priority Critical patent/JP2004503201A/en
Priority to AU86913/98A priority patent/AU8691398A/en
Priority to EP98938377A priority patent/EP1007967A2/en
Publication of WO1999006834A2 publication Critical patent/WO1999006834A2/en
Publication of WO1999006834A3 publication Critical patent/WO1999006834A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method for identifying a binding molecule having selective affinity for a ligand. The method consists of selectively immobilizing a diverse population of binding molecules to a solid support, simultaneously contacting the diverse population immobilized on the solid support with two or more ligands and determining at least one binding molecule which selectively binds to one or more of the ligands. The invention additionally provides a method for identifying an antibody having selective affinity for a tumor antigen. The method consists of selectively immobilizing a diverse population of antibodies to a solid support, simultaneously contacting the diverse population immobilized on the solid support with two or more tumor antigens and determining at least one antibody which selectively binds to one or more of the tumor antigens. The invention also provides an isolated binding polypeptide selective for a tumor antigen. Further provided by the present invention is a Complementarity Determining Region (CDR) or functional fragment thereof of an antibody selective for a tumor antigen.
PCT/US1998/016280 1997-08-04 1998-08-04 Methods for identifying ligand specific binding molecules WO1999006834A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000505515A JP2004503201A (en) 1997-08-04 1998-08-04 Methods for identifying ligand-specific binding molecules
AU86913/98A AU8691398A (en) 1997-08-04 1998-08-04 Methods for identifying ligand specific binding molecules
EP98938377A EP1007967A2 (en) 1997-08-04 1998-08-04 Methods for identifying ligand specific binding molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90582597A 1997-08-04 1997-08-04
US08/905,825 1997-08-04

Publications (2)

Publication Number Publication Date
WO1999006834A2 WO1999006834A2 (en) 1999-02-11
WO1999006834A3 true WO1999006834A3 (en) 1999-05-14

Family

ID=25421544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/016280 WO1999006834A2 (en) 1997-08-04 1998-08-04 Methods for identifying ligand specific binding molecules

Country Status (3)

Country Link
EP (1) EP1007967A2 (en)
AU (1) AU8691398A (en)
WO (1) WO1999006834A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520366A (en) * 1997-10-09 2001-10-30 イクシス， インコーポレイテッド Methods for identifying optimal binding ligands for receptors
WO1999023107A1 (en) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
WO2001027327A2 (en) 1999-10-08 2001-04-19 Protogene Laboratories, Inc. Method and apparatus for performing large numbers of reactions using array assembly
SE9903895D0 (en) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101389791A (en) 2005-12-23 2009-03-18 维文蒂阿生物技术股份有限公司 Methods for generating and screening fusion protein libraries and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
CA3049612C (en) 2008-04-24 2023-01-10 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
CN102076355B (en) 2008-04-29 2014-05-07 Abbvie公司 Dual varistructure domain immunoglobulins and uses thereof
BRPI0911758A8 (en) 2008-05-09 2017-10-10 Abbott Lab ANTIBODIES FOR RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR20110031369A (en) 2008-07-08 2011-03-25 아보트 러보러터리즈 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
PE20121647A1 (en) 2009-08-29 2012-12-31 Abbvie Inc THERAPEUTIC BINDING PROTEINS TO DLL4
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CN102666875A (en) 2009-10-15 2012-09-12 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
RU2605928C2 (en) 2010-03-02 2016-12-27 Эббви Инк. Therapeutic dll4-binding proteins
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
BR112013002578A2 (en) 2010-08-03 2019-05-14 Abbvie Inc. double variable domain immunoglobins and their uses
AU2011291462A1 (en) 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201307388A (en) 2010-12-21 2013-02-16 Abbott Lab IL-1 binding proteins
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
AR091755A1 (en) 2012-07-12 2015-02-25 Abbvie Inc PROTEINS OF UNION TO IL-1
KR20200079565A (en) 2012-08-31 2020-07-03 이뮤노젠 아이엔씨 Diagnostic assays and kits for detection of folate receptor 1
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
CN105209616A (en) 2013-03-14 2015-12-30 雅培制药有限公司 HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
EP2968526A4 (en) 2013-03-14 2016-11-09 Abbott Lab Hcv antigen-antibody combination assay and methods and compositions for use therein
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN116284404A (en) 2016-06-08 2023-06-23 艾伯维公司 anti-B7-H3 antibodies and antibody drug conjugates
MX2019005661A (en) 2016-11-16 2019-10-07 Janssen Biotech Inc Method of treating psoriasis with anti-il-23 specific antibody.
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
JP7069476B2 (en) 2017-01-06 2022-05-18 博奥信生物技▲術▼（南京）有限公司 ErbB2 antibody and its use
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
CN117050176A (en) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 Humanization method based on three-dimensional structure
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
JP2021513357A (en) 2018-02-14 2021-05-27 ビエラ バイオ インコーポレイテッド Antibodies to cat McDonough sarcoma (FMS) -like tyrosine kinase 3 receptor ligand (FLT3L) and their use for treating autoimmune and inflammatory diseases
EP3762015A4 (en) 2018-03-05 2022-04-27 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
BR112020017701A2 (en) 2018-03-12 2020-12-29 Zoetis Services Llc ANTI-NGF ANTIBODIES AND METHODS OF THE SAME
JP2021530697A (en) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド Sustained response predictor after treatment with anti-IL23 specific antibody
PL3883606T3 (en) 2018-09-24 2023-11-27 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
CN113164780A (en) 2018-10-10 2021-07-23 泰洛斯治疗公司 anti-LAP antibody variants and uses thereof
CN113395979A (en) 2018-11-20 2021-09-14 詹森生物科技公司 Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
JP2022525145A (en) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド A production method for producing an anti-IL12 / IL23 antibody composition.
BR112021018441A2 (en) 2019-03-18 2023-02-28 Janssen Biotech Inc METHOD FOR TREATMENT OF PSORIASIS IN PEDIATRIC INDIVIDUALS WITH ANTI-IL12/IL23 ANTIBODY
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
AU2022238849A1 (en) 2021-03-17 2023-08-31 Receptos Llc Methods of treating atopic dermatitis with anti il-13 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000295A1 (en) * 1989-06-30 1991-01-10 Oncogen Limited Partnership Novel antibodies reactive with human carcinomas
WO1995006067A1 (en) * 1993-08-21 1995-03-02 Imperial Cancer Research Technology Limited Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
WO1995035374A1 (en) * 1994-06-21 1995-12-28 Dan Michael D Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
EP0699756A1 (en) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000295A1 (en) * 1989-06-30 1991-01-10 Oncogen Limited Partnership Novel antibodies reactive with human carcinomas
WO1995006067A1 (en) * 1993-08-21 1995-03-02 Imperial Cancer Research Technology Limited Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
WO1995035374A1 (en) * 1994-06-21 1995-12-28 Dan Michael D Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
EP0699756A1 (en) * 1994-08-04 1996-03-06 Bristol-Myers Squibb Company Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. YELTON ET AL.: "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, 15 August 1995 (1995-08-15), Baltimore, MD, USA, pages 1994 - 2004, XP002096491 *
I. SANZ ET AL.: "The smaller human VH gene families display remarkably little polymorphism.", THE EMBO JOURNAL, vol. 8, no. 12, 1 December 1989 (1989-12-01), Oxford, GB, pages 3741 - 3748, XP002096490 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382535B2 (en) 2000-04-17 2016-07-05 Dyax Corp. Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8895475B2 (en) 2000-12-18 2014-11-25 Robert Charles Ladner Focused libraries of genetic packages
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US9481735B2 (en) 2009-03-05 2016-11-01 Abbvie Inc. IL-17 binding proteins
US9481736B2 (en) 2009-03-05 2016-11-01 Abbvie, Inc. IL-17 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US9303085B2 (en) 2010-05-14 2016-04-05 Abbvie Inc. IL-1 binding proteins
US9409986B2 (en) 2010-05-14 2016-08-09 Abbvie Inc. IL-1 binding proteins
US9441038B2 (en) 2010-05-14 2016-09-13 Abbvie Inc. IL-1 binding proteins
US9447183B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US9447184B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies

Also Published As

Publication number Publication date
EP1007967A2 (en) 2000-06-14
WO1999006834A2 (en) 1999-02-11
AU8691398A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
WO1999006834A3 (en) Methods for identifying ligand specific binding molecules
CA2162568A1 (en) Method and reagent for simultaneously assaying one or more ligands in a group of preselected ligands
CA2224674C (en) Immunoassay and kit with two reagents that are cross-linked if they adhere to an analyte
AU3684197A (en) Assay reagents and devices
DE69503903D1 (en) POSITIVE AND POSITIVE / NEGATIVE CELL SELECTION BROKEN BY PEPTIO RELEASE
JP2003530543A5 (en)
IL123294A0 (en) Monoclonal antibody BR110 and uses thereof
MX161338A (en) APPARATUS FOR IMMUNO ASSAYS OF A BINDING RECEIVER
IL154000A (en) Method employing antibodies for diagnosing rheumatoid arthritis
ATE426158T1 (en) MICROFLUIDIC EXTRACTION METHOD
JPH06508214A (en) Methods and reagents for performing ion capture digoxin assays
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
EP0829723A3 (en) Homogeneous detection method for the determination of sub-populations of an analyte
CA1194415A (en) Immunoglobulin half-molecules and process for producing hybrid antibodies
CA2411392A1 (en) Tetrameric antibody complexes for blocking non-specific binding of antigens
CA2067584A1 (en) Agglutinant complex as blood typing reagent
JP2002525607A5 (en)
WO2000037941A3 (en) A METHOD OF DETECTING AND/OR QUANTIFYING A SPECIFIC IgE ANTIBODY IN A LIQUID SAMPLE
AU687932B2 (en) A method for the determinatin of antigens or antibodies in the presence of an immune complex
CA2483408A1 (en) Sandwich assay and kit
WO1999000424A3 (en) Antibodies and other binding molecules specific for hepatitis b viral antigens
MY137138A (en) Diagnostic reagents and preparing methods thereof
JP2001183375A (en) Enzyme marker antibody
Andersson Antigen-antibody reactions: A study of functional structures and non-immunological interactions.
Wingren Surface properties of antibodies and their complexes with antigens studied by LLPC.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998938377

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998938377

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998938377

Country of ref document: EP